The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst
: First question, just given that the RDEB community is pretty tightened it and aware of the clinical landscape. What's your expectation on how much
awareness there will be moving closer to an approval decision? I guess I understand that you're going to be building a sales force and getting the
word out there. But do you also anticipate this to be one of the situations where you can get people coming inbound to you?
Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst
: Okay. And then I wanted to ask you on epidemiology. I know that this is a rare disease, but not that rare to the point where you have a good sense
of how many patients are available. So first, I wanted to ask how you think, given the landscape with 2 potential commercial therapies could help
impact or perhaps drive awareness on epidemiology. And then given this impressive data set that you recently had in Japan, I'm wondering if
you've had people approach you to perhaps look at markets besides the usual U.S. and Europe that we would think about.
Madhav Vasanthavada
Yes. I think the way we are looking at this opportunity is by wounds, right? And that's what we are hearing from physicians that it's not just about
the number of patients, but it's the different types of wounds that each patient has got. And we are hearing from physicians that both these
therapies are for different types of wounds. And so if you look at the current base of bolus patients and/or prevalent patients, we have estimates
of up to 350, which is what are the reported numbers. But as we know that about 1,100 is what has been identified by Crystal, who have already
gone to the centers of excellence. So from our standpoint at the time of launch and given our manufacturing capacity, we think these hundreds
of thousands of patients which are out there.
For us, we are going to be well satiated with the patient numbers out there in terms of the way we will expand our capacity ramp up. And so that's
what is very encouraging at least from our perspective of supplying these patients. And as we have more therapies and awareness, the diagnosis
also we expect to increase. And many a times, these patients under ICD code 81.2 is what is used for RDEB, but several patients are also misdiagnosed
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 08, 2023 / 12:30PM, ABEO.OQ - Q2 2023 Abeona Therapeutics Inc Earnings Call
or put in other classifications. So I think having the right diagnosis and awareness is going to help identify RDEB patients in particular more so. With
regards to other than U.S. markets, absolutely, we do have interest that is coming in from pharma companies in Europe, as well as actually in
Japanese markets where there is interest and those discussions are ongoing to see as to when is the right time to look into expansion.
Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst
: Great. And wishing you all the best this quarter.
|
